5-HTP is a naturally occurring indole amino acid and serotonin precursor found in the body and studied in humans mainly for Mental Health, Sleep, Obesity and Weight Regulation, and related serotonergic pharmacology contexts (Research).
5-HTP is researched as an administered serotonin precursor rather than as a nutrient with established deficiency criteria, and the cited human literature consists mainly of small randomized trials, older clinical studies, and a few formulation- or context-specific investigations across depression-related symptoms, sleep quality, obsessive-compulsive symptoms, migraine prophylaxis, and appetite or weight outcomes (Review) (Review). The strongest recurring human literature is in depression-related symptom research, but even there reviews describe important heterogeneity and limited trial quality (Review) (Review). Other domains are supported by narrower trial programs, shorter durations, or formulation-specific evidence rather than a broad replicated literature (Research) (Research).
Ingredient Snapshot
- Entity: 5-HTP (5-Hydroxytryptophan)
- Chemical or biological class: Indole amino acid; intermediate in serotonin biosynthesis (Research)
- Endogenous vs exogenous: Endogenous compound that can also be administered orally (Research)
- Primary human research domains: Mental Health; Sleep; Obesity and Weight Regulation (Review) (Research) (Research)
- Common study formats: Small randomized trials, crossover pharmacology studies, open clinical studies, and systematic reviews/meta-analyses (Research) (Research) (Review)
- Pharmacokinetic characterization status: Human pharmacology has been studied, but formulation-specific and dose-specific characterization remains limited in the cited sources (Research)
- Regulatory context (U.S./EU): The cited U.S. source provides compounding-policy context for oral oxitriptan rather than general approval, while the cited EU materials include an EFSA health-claim evaluation and a national novel-food enforcement context (FDA) (EFSA) (EFSA)
Research Snapshot
5-HTP is best characterized in human research as an orally administered serotonin precursor studied most often in depression-related symptoms, with smaller direct-use literatures in sleep quality and appetite or weight-related outcomes (Review) (Research) (Research). Narrower condition-specific trials have also examined adjunctive obsessive-compulsive symptom treatment and migraine prophylaxis, but these areas are less replicated and do not define the ingredient’s main research identity (Research) (Research).
Typical studied human exposures in the cited library range from 50 mg/day in a Parkinson’s disease depression trial to 750 mg/day in a short appetite and weight study, with additional single-dose pharmacology challenges at 100 mg, 200 mg, and 300 mg given with carbidopa (Research) (Research) (Research). The evidence base is limited by small samples, short durations, older study designs, and important formulation or co-treatment differences, including adjunctive fluoxetine use and carbidopa coadministration (Research) (Research). Overall, the human evidence is limited to mixed rather than mature, with real interventional signals but incomplete standardization and uneven replication across domains (Review) (Review).
Introduction
5-HTP, also called 5-hydroxytryptophan or oxitriptan, is a naturally occurring intermediate on the pathway from tryptophan to serotonin, and this biochemical role is the main reason it has been studied as an administered compound in human research (Research) (FDA). In the cited materials, the focus is much more on administered oral use and serotonergic pharmacology than on ordinary food composition (Research).
People usually look up 5-HTP because it is associated with serotonin biology and has been studied in humans for depression-related symptoms, sleep quality, appetite or weight outcomes, and a smaller number of other serotonin-linked clinical questions (Review) (Research) (Research). Interest has persisted because some controlled trials reported favorable findings, while review-level assessments continue to emphasize small samples, short follow-up, and inconsistent methods across the broader literature (Review) (Review).
This article is informational only, describes 5-HTP as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- 5-HTP is a serotonin precursor that occurs naturally in the body and has been studied as an orally administered compound in several serotonin-related research areas (Research).
- The strongest recurring human literature in the cited sources concerns depression-related symptoms, but systematic reviews describe this evidence as heterogeneous and not sufficient for firm conclusions (Review) (Review).
- Randomized human studies in the cited library also examined Sleep, Obsessive-Compulsive Disorder adjunctive use, and Obesity and Weight Regulation, but these areas are supported by fewer trials and narrower populations (Research) (Research) (Research).
- Human exposures in the cited studies range from 50 mg/day to 750 mg/day, with additional single-dose pharmacology studies at 100-300 mg alongside carbidopa (Research) (Research) (Research).
- The most directly reported tolerability issues in the cited sources are gastrointestinal effects such as nausea, vomiting, and other gastrointestinal disturbances (Research) (Research).
- U.S. and EU regulatory context in the cited sources is framework-specific rather than a broad efficacy endorsement, including FDA compounding-policy context and EFSA or national European food-regulatory context (FDA) (EFSA) (EFSA).
Human Research Findings by Condition
Mental Health
Human research on Mental Health is strongest for depression-related symptoms, with narrower randomized evidence in Parkinson’s disease-related depression and adjunctive obsessive-compulsive symptom treatment (Review) (Research) (Research). The overall signal is mixed because some trials reported improvement, while review-level assessments emphasize methodological limitations and inconsistency across studies (Review) (Review).
Dose studied: 50 mg/day
Population: Patients with Parkinson’s disease and depressive symptoms
Duration: 4 weeks
Study summary:
A randomized, double-blind, placebo-controlled crossover trial examined oral 5-HTP in patients with Parkinson’s disease and reported significant improvement in depressive symptoms compared with placebo, while apathy did not improve clearly. This result applies only within the conditions of the cited study.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Dose studied: 150-300 mg/day
Population: 59 patients with depressive symptoms
Duration: 3 weeks
Study summary:
An open clinical evaluation reported favorable responses in depressive symptoms during short-term treatment, with gastrointestinal disturbances described as the main side effects. This evidence does not establish long-term or general-population effects.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Optional supporting context citation: (Review)
Sleep
Human studies on Sleep are limited and currently anchored mainly by one randomized trial in older adults rather than a broad replicated sleep literature (Research). This finding is limited to the study population and duration.
Dose studied: 100 mg/day
Population: Older adults
Duration: 12 weeks
Study summary:
A randomized controlled trial evaluated oral 5-HTP for 12 weeks and reported improvement in some sleep-quality components, with effects described as more evident among poorer sleepers and accompanied by higher serum serotonin concentrations. The findings are specific to the study design and may not generalize beyond it.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Obesity and Weight Regulation
Human research on Obesity and Weight Regulation includes a short placebo-controlled study in overweight patients with non-insulin-dependent diabetes and a more recent preliminary trial in exercise-trained adults with more limited effects (Research) (Research). Taken together, the cited evidence is narrower and more mixed than the mood-related literature.
Dose studied: 750 mg/day
Population: Overweight outpatients with non-insulin-dependent diabetes
Duration: 2 weeks
Study summary:
A double-blind, placebo-controlled study used oral 5-HTP and reported lower daily energy intake, lower carbohydrate and fat intake, and body-weight reduction among completers over a short study period. This finding is limited to the study population and duration.
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Dose studied: 100 mg/day
Population: Exercise-trained men and women
Duration: 8 weeks
Study summary:
A preliminary randomized trial using a branded 5-HTP preparation reported no clear change in food intake or lean mass, although a small between-group difference in fat-mass change was observed. This result applies only within the conditions of the cited study.
Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)
Neurological Health
Human research on Neurological Health in the cited library is narrow and centers mainly on migraine prophylaxis rather than a broader neurological outcomes literature (Research). The evidence is older, and the exact dose is not clearly extractable from the cited record reviewed.
Dose studied: Exact oral prophylactic dose not clearly extractable from the cited record
Population: 124 patients with migraine
Duration: Not clearly extractable from the cited record
Study summary:
A randomized comparative trial reported improvement in 71% of patients treated with 5-HTP, with the effect described as more evident for attack intensity and duration than for attack frequency. The findings are specific to the study design and may not generalize beyond it.
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
The cited human exposure literature for 5-HTP is mainly oral direct-use research, with a mix of low-dose randomized trials, short higher-dose appetite studies, and single-dose pharmacology challenges rather than a standardized dose-response program across one condition (Research) (Research) (Research). The lowest documented repeated daily exposure in the cited library is 50 mg/day in a Parkinson’s disease depression study, but that low-dose band comes from a narrow clinical context rather than the main depression review literature. Some studied regimens also involve adjunctive fluoxetine use, carbidopa coadministration, or a branded preparation, which limits straightforward cross-study comparison (Research) (Research).
This lowest documented repeated daily dose in the cited library comes from a randomized crossover study in patients with Parkinson’s disease and depressive symptoms. Researchers used oral 5-HTP for 4 weeks and observed improvement in depressive symptom scores compared with placebo, while apathy did not change clearly. This is a condition-specific low-dose finding rather than a general-purpose dose anchor across all 5-HTP research. It is most useful for showing that clinically studied exposures in the cited literature begin below the more commonly discussed mid-range doses.
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: This dose band is tied to Parkinson’s disease-related depression and may not generalize to other populations. (Research)
A 12-week randomized trial in older adults used oral 5-HTP at 100 mg/day and reported improvement in some sleep-quality components, especially among poorer sleepers (Research). A separate 8-week preliminary randomized study using a branded 5-HTP preparation in exercise-trained adults also used 100 mg/day but found no clear change in food intake and only a modest difference in fat-mass change (Research). Together, these studies show that the same nominal dose has been studied in very different populations with different endpoints and mixed results. This makes interpretation more dependent on population and outcome than on dose alone.
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: One of the studies used a branded preparation, so this band is not a clean single-formulation evidence tier.
These single-dose pharmacology challenges were studied in 15 healthy male volunteers using oral 5-HTP together with carbidopa in a placebo-controlled crossover design (Research). Researchers reported dose-related neuroendocrine effects and increasing nausea and vomiting as the dose increased, with dropout rising at the 300 mg exposure. This is a pharmacology and tolerability band rather than an efficacy band, and the coadministration with carbidopa means it should not be treated as directly equivalent to ordinary oral use contexts. It is still important because it provides some of the clearest human dose-response information in the cited library.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This was a short pharmacology study with carbidopa coadministration, not a longer outcome trial.
A 12-week randomized double-blind trial used oral 5-HTP at 100 mg twice daily as an adjunct to fluoxetine in patients with moderate to severe obsessive-compulsive disorder (Research). Researchers reported better Y-BOCS outcomes in the combination group than in the fluoxetine-plus-placebo group. Because this study tested adjunctive treatment rather than 5-HTP alone, the findings are best interpreted as combination-context evidence. The regimen also represents a repeated daily exposure higher than the 100 mg/day single-agent trials.
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: This band reflects adjunctive use with fluoxetine rather than standalone 5-HTP.
An older open clinical evaluation in 59 patients with depressive symptoms used oral 5-HTP across a daily range of 150-300 mg for 3 weeks (Research). Favorable responses were reported, and gastrointestinal disturbances were identified as the main side effects. This band is often cited in short-term mood-related research because it represents direct administered use without the Parkinson’s disease or adjunctive-OCD context of some lower-dose studies. However, the open design substantially limits confidence.
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The study was open-label and short-term, which limits interpretation.
The highest repeated daily dose in the cited library comes from a 2-week double-blind placebo-controlled study in overweight outpatients with non-insulin-dependent diabetes (Research). Researchers reported lower energy intake, reduced carbohydrate and fat intake, and body-weight reduction among completers during this short intervention. This higher-dose band is notable because it sits in an appetite and weight context rather than the mental-health trials that dominate the broader 5-HTP literature. It therefore helps show that exposure range varies substantially by research question.
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The study was short and conducted in a specific overweight diabetic population.
The cited migraine prophylaxis trial reported comparative improvement versus methysergide, particularly for attack intensity and duration, but the exact oral 5-HTP dose is not clearly extractable from the reviewed record in this evidence set (Research). That means the study supports the existence of human migraine research but does not provide a clean dose anchor for a standardized ladder. It is best treated as contextual evidence alongside the explicit dose bands above.
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: The exact standalone dose could not be clearly extracted from the cited record.
Key Takeaways from Human Research
- Human evidence for 5-HTP is most developed in depression-related symptom research, but review-level assessments still describe the literature as heterogeneous and not definitive (Review) (Review).
- Randomized human data in the cited library show narrower but real signals in Sleep, Obsessive-Compulsive Disorder adjunctive treatment, and Parkinson’s disease-related depressive symptoms (Research) (Research) (Research).
- Appetite and body-weight findings have been studied in specific populations, including overweight diabetic patients, but results are not supported by a broad modern replication base (Research) (Research).
- Human exposures in the cited sources span from 50 mg/day to 750 mg/day, with additional short single-dose pharmacology studies at 100-300 mg plus carbidopa (Research) (Research) (Research).
- The most consistent tolerability issues in the cited library are gastrointestinal symptoms, while broader long-term safety characterization remains limited in the reviewed sources (Research) (Research).
Ingredient Identity
- Official name(s): 5-Hydroxytryptophan; oxitriptan
- Synonyms: 5-HTP; 5-hydroxy-L-tryptophan
- Classification: Indole amino acid; serotonin precursor
- CAS number: Not clearly established in the cited source set
- Endogenous vs exogenous: Endogenous compound that can also be administered orally
Origin & Natural Occurrence
5-HTP is produced in the body as an intermediate step in the conversion of the amino acid tryptophan into serotonin, which is why it is usually discussed in relation to serotonergic physiology rather than as a conventional dietary nutrient target (Research). In the cited regulatory material, it also appears under the name oxitriptan, especially in drug-compounding context (FDA).
The cited sources focus much more on administered oral 5-HTP and pharmacology than on ordinary food composition. Manufacturing or commercial preparation details are not characterized in depth within the cited library, so this article keeps its origin discussion closely tied to endogenous biochemistry and studied administered forms (Research).
How It Behaves in the Body
In plain language, 5-HTP matters because it sits between tryptophan and serotonin in the body’s serotonin-production pathway. When administered, it is studied as a way to increase precursor availability for serotonin-related signaling, which is why human research has focused on mood, sleep, appetite, and other serotonin-linked outcomes (Research) (Review).
The cited pharmacology study shows that oral 5-HTP can produce measurable human neuroendocrine responses, especially when given with carbidopa, a drug used in that study context to modify peripheral metabolism (Research). That finding supports biological activity in humans, but it does not by itself establish clinical benefit for a condition.
Across the cited clinical literature, researchers interpret 5-HTP mainly through its role as a serotonergic precursor, not as a receptor-targeted drug with one narrowly defined outcome (Review) (Review). What is well established in the cited sources is the biochemical rationale and the existence of human physiological effects; what remains less established is how consistently those effects translate into clinically meaningful outcomes across conditions, doses, and formulations (Review).
Absorption & Delivery Formats
Oral immediate-release is the main delivery format represented in the cited human literature, including studies in depression-related symptoms, sleep, appetite, obsessive-compulsive symptoms, and pharmacology challenge designs (Research) (Research) (Research). These studies show that oral exposure is biologically active, but they do not provide a full modern comparison of oral formulation technologies.
Evidence for oral extended-release is not clearly established in the cited source set. The reviewed studies do not provide a strong basis for comparing immediate-release with sustained-release delivery.
Evidence for sublingual and transdermal delivery is not established in the cited library, so no claims are made here about those routes.
An injectable / IV research or clinical delivery context is also not established in the cited source set for this article. The available evidence is centered on oral administration and oral pharmacology context (Research).
Quick Facts at a Glance
Onset (reported)
The cited human studies mainly report outcomes over weeks rather than hours, with mood-related, sleep, or appetite endpoints typically assessed after short intervention periods such as 2, 3, 4, 8, or 12 weeks (Research) (Research) (Research). Short-term physiological effects were observed in the pharmacology challenge study, but that design measured neuroendocrine responses rather than clinical onset for a health outcome (Research).
Time to peak (Tmax)
A precise Tmax value is not clearly provided in the cited source set used for this article. The cited library does show that short-term physiological responses can occur after single oral doses in a controlled pharmacology setting, but full PK timing parameters are incompletely characterized here (Research).
Half-life (t½)
A precise human t½ is not clearly extractable from the cited library. The available pharmacology evidence supports biological activity after oral dosing but does not provide a complete modern half-life characterization in the sources cited here (Research).
Typical duration
Typical intervention durations in the cited human studies range from 2 weeks to 12 weeks, depending on the research question (Research) (Research). This means the current article is supported mainly by short- to medium-duration human research rather than long-term outcome studies.
Absorption routes studied
The cited human evidence is dominated by oral administration (Research) (Research). Other routes are not meaningfully characterized in the sources reviewed for this article.
Formulation differences
Some studies appear to use standard oral 5-HTP, while others involve carbidopa coadministration, adjunctive use with fluoxetine, or a branded preparation, which complicates simple cross-study comparisons (Research) (Research) (Research). These differences matter because formulation and co-treatment context can change both interpretation and generalizability.
Variability drivers
The cited literature suggests that variability may arise from population differences, coadministered agents, study design, and outcome selection more than from one simple universal dose rule (Review) (Review). For example, low-dose effects were reported in Parkinson’s disease-related depression, while higher-dose appetite studies involved overweight diabetic patients, and these are not interchangeable contexts (Research) (Research).
Tolerance / adaptation
The cited library does not establish a clear long-term tolerance pattern for 5-HTP. What is better characterized in the reviewed sources is short-term tolerability, especially gastrointestinal adverse effects and dose-related nausea in pharmacology studies (Research) (Research).
Evidence strength snapshot
The overall human evidence base is limited to mixed, with the best coverage in depression-related symptoms and narrower randomized evidence in sleep, obsessive-compulsive symptoms, and appetite-related outcomes (Review) (Review). Pharmacology is clearer than long-term clinical effectiveness, and regulatory context is framework-specific rather than an efficacy endorsement (Research) (FDA).
Safety, Interactions & Regulation
The most directly described adverse effects in the cited human literature are gastrointestinal symptoms, including nausea, vomiting, and other gastrointestinal disturbances (Research) (Research). In the placebo-controlled pharmacology challenge, nausea and vomiting increased with higher single doses, and dropout rose at the 300 mg exposure given with carbidopa (Research).
Interaction interpretation should remain cautious because some studies used 5-HTP with carbidopa or with fluoxetine, which shows that coadministration contexts exist in the clinical literature but does not by itself define a complete interaction profile across all serotonergic drugs (Research) (Research). Population-specific findings in Parkinson’s disease, older adults, overweight diabetic patients, and obsessive-compulsive disorder adjunctive therapy also mean that safety observations may not generalize across all populations or formulations (Research) (Research) (Research).
A historical safety context cited here is the eosinophilia-myalgia syndrome contamination episode associated with contaminated L-tryptophan products, which does not establish a clean ingredient-specific 5-HTP toxicity signal but remains relevant as contamination history for serotonergic amino-acid products (Research).
In the U.S., the cited FDA source provides compounding-policy context for certain oral oxitriptan (5-HTP) drug products for BH4 deficiency and does not constitute drug approval or efficacy evaluation (FDA). Within the context of the cited EU materials, EFSA evaluated a health-claim submission related to satiety and energy intake rather than issuing a broad efficacy authorization for all uses (EFSA). Separately, the cited Greek EOF page describes a national regulatory position treating 5-HTP as novel-food-related context not permitted in food products under that authority’s jurisdiction, based on the cited food-use-history framework (EFSA).
Evidence Overview
Human evidence for 5-HTP is strongest in Mental Health, more mixed and narrow in Sleep and Obesity and Weight Regulation, and still limited in smaller domains such as migraine prophylaxis or adjunctive obsessive-compulsive symptom studies (Review) (Research) (Research) (Research) (Research). The dominant human evidence types are small randomized trials, older open clinical studies, and short pharmacology investigations rather than a large standardized development program (Review) (Review). Confidence is not higher because the cited literature remains heterogeneous in design, duration, dose, and formulation context (Review).
The best-developed domain is mood-related research. Older open and randomized studies, along with later systematic reviews and meta-analyses, suggest that 5-HTP may influence depressive symptoms in some settings, but the cited reviews repeatedly note that study quality, sample size, duration, and dosing differ enough to limit confidence in broad conclusions (Research) (Review) (Review). A more specific randomized crossover trial in Parkinson’s disease found improvement in depressive symptoms at 50 mg/day, but that finding does not establish the same effect in general depression populations (Research).
Outside mood-related studies, the evidence footprint becomes narrower. Sleep data in the cited library are anchored mainly by one 12-week randomized trial in older adults using 100 mg/day, which reported improvement in some sleep-quality components rather than a broad set of replicated sleep outcomes (Research). Appetite and weight-related findings include a short placebo-controlled trial at 750 mg/day in overweight diabetic patients reporting lower energy intake and body-weight reduction, but a more recent 100 mg/day preliminary trial in exercise-trained adults reported much more limited effects, highlighting how population and endpoint choice can shift the apparent signal (Research) (Research). The obsessive-compulsive disorder trial is narrower because it studied 5-HTP as an adjunct to fluoxetine rather than as a standalone intervention (Research). Migraine research is present, but the exact standalone dose was not clearly extractable from the cited indexed record reviewed for this article (Research).
Pharmacology evidence is clearer than long-term clinical effectiveness. The cited human challenge study with carbidopa demonstrates dose-related neuroendocrine responses and dose-related nausea and vomiting across 100 mg, 200 mg, and 300 mg single doses, which helps confirm biological activity but does not resolve condition-specific efficacy questions (Research). The sources cited here also provide only limited long-term safety detail and incomplete modern PK characterization, which further constrains confidence in broad generalization (Research) (Research).
Evidence Confidence Classification
The overall human evidence for 5-HTP is Limited / Mixed, because multiple human studies exist but they remain constrained by small samples, short follow-up, heterogeneous designs, and uneven replication across domains (Review) (Review).
Interventional human evidence is present in mood-related symptoms, sleep, appetite or weight outcomes, obsessive-compulsive adjunctive therapy, and migraine prophylaxis, but many studies are small, short, older, or context-specific (Research) (Research) (Research) (Research). Observational evidence is not the dominant part of the cited library, while mechanistic and pharmacology evidence mainly supports serotonergic plausibility and short-term physiological activity rather than firm clinical effectiveness (Research). Regulatory context in the cited sources is framework-level and does not function as proof of efficacy (FDA) (EFSA).
Similar Ingredients & Comparators
Combination Context
5-HTP + Fluoxetine:
This combination was studied as adjunctive treatment in moderate to severe obsessive-compulsive disorder, where 5-HTP at 100 mg twice daily was added to fluoxetine and was associated with better Y-BOCS outcomes than fluoxetine plus placebo over 12 weeks (Research). The main limitation is that this is combination-context evidence rather than standalone 5-HTP evidence.
5-HTP + Carbidopa:
This combination was used in a placebo-controlled crossover pharmacology study in healthy men to examine dose-related neuroendocrine effects after single 5-HTP doses of 100 mg, 200 mg, and 300 mg (Research). The main limitation is that this was a short pharmacology and tolerability design, so it should not be read as direct clinical efficacy evidence.
FAQ
What is this ingredient?
5-HTP is 5-hydroxytryptophan, a naturally occurring serotonin precursor that can also be administered orally in human research (Research). It is usually studied because it sits on the biochemical pathway between tryptophan and serotonin (Research). In the cited regulatory material, it also appears under the name oxitriptan in compounding-policy context (FDA).
What does human research study it for?
Human research has studied 5-HTP mainly for Mental Health, Sleep, and Obesity and Weight Regulation outcomes, with narrower studies in migraine prophylaxis and obsessive-compulsive adjunctive treatment (Review) (Research) (Research). Much of this work is tied to serotonin-related physiology rather than one single disease model (Research). The cited literature includes randomized trials, open clinical studies, and pharmacology studies rather than one unified development program (Review).
What are the best-supported uses?
The best-supported human research area in the cited sources is depression-related symptom research, because it has the most recurring trial and review coverage (Review) (Review). Even so, the reviews do not treat the evidence as definitive because of heterogeneity and trial limitations (Review). There are also narrower randomized findings in sleep quality, Parkinson’s disease-related depressive symptoms, and adjunctive obsessive-compulsive symptom research (Research) (Research) (Research).
Where is evidence mixed or limited?
Evidence is mixed or limited in several important ways (Review) (Review). Weight-related findings differ across populations and doses, with a short higher-dose study in overweight diabetic patients showing favorable results and a lower-dose preliminary trial in exercise-trained adults showing much weaker effects (Research) (Research). Sleep evidence in this library is also narrow because it relies mainly on one randomized study in older adults (Research). Migraine evidence exists, but the exact standalone dose was not clearly extractable from the cited record reviewed for this article (Research).
How quickly does it act (onset)?
The cited clinical literature mainly measures outcomes over weeks, not immediate symptom changes (Research) (Research) (Research). Short-term physiological effects were observed in a single-dose pharmacology study, but that study focused on neuroendocrine responses rather than clinical onset for mood, sleep, or weight outcomes (Research). So, the available cited evidence is better for short-term biological activity and short-course trials than for precise onset timing in routine use contexts.
What affects absorption and variability?
Variability appears to be influenced by dose, population, study design, formulation, and coadministered agents in the cited literature (Review) (Research). Some studies used 5-HTP alone, while others used it with carbidopa, with fluoxetine, or as a branded preparation, making cross-study comparison less straightforward (Research) (Research) (Research). The cited library does not provide a full modern PK comparison across delivery formats.
Is tolerance reported?
Long-term tolerance is not clearly characterized in the cited library (Research). What is reported more clearly is short-term tolerability, especially nausea, vomiting, and other gastrointestinal disturbances in some studies (Research) (Research). That means the reviewed evidence is stronger for acute tolerability signals than for long-term adaptation patterns.
Why do studies disagree?
Studies likely disagree because the cited evidence base mixes different populations, different doses, different durations, and different intervention contexts (Review) (Review). Some trials are open-label, some are randomized, some involve combination treatment, and some focus on short-term pharmacology rather than clinical outcomes (Research) (Research) (Research). Those differences make the overall literature harder to interpret as one consistent evidence stream.
What ingredients is it commonly combined with and why?
In the cited human literature, 5-HTP was combined with fluoxetine to test adjunctive treatment for obsessive-compulsive disorder and with carbidopa in a pharmacology study to examine physiological responses after oral dosing (Research) (Research). These are research-context combinations, not a general statement about routine combination practice. The reason for combining them differed by study: one aimed at symptom outcomes and the other at pharmacologic response measurement.
What foods naturally contain this ingredient?
The cited sources used for this article do not provide a clear food-composition profile for 5-HTP (Research). Instead, they primarily describe 5-HTP as an endogenous intermediate and an administered oral research compound (Research). This article therefore does not make broader food-content claims.
How is it regulated?
Regulatory treatment in the cited sources is framework-specific and jurisdiction-specific, not one universal status (FDA) (EFSA) (EFSA). In the U.S., the cited FDA page provides compounding-policy context for oral oxitriptan and does not represent drug approval or efficacy evaluation (FDA). In the cited EU materials, EFSA reviewed a health-claim submission related to satiety, while the cited Greek EOF page describes a national novel-food-related enforcement position under that authority’s framework (EFSA) (EFSA).
Resources
- 5-Hydroxytryptophan for depression – PubMed – https://pubmed.ncbi.nlm.nih.gov/307522/
- Tryptophan and 5-hydroxytryptophan for depression (Cochrane review) – PubMed – https://pubmed.ncbi.nlm.nih.gov/11687048/
- Systematic review and meta-analysis on 5-HTP and depression – PubMed – https://pubmed.ncbi.nlm.nih.gov/31504850/
- Earlier meta-analysis on 5-HTP and depression – PubMed – https://pubmed.ncbi.nlm.nih.gov/12169147/
- 5-HTP in Parkinson’s disease-related depression – PubMed – https://pubmed.ncbi.nlm.nih.gov/32067288/
- 5-HTP and sleep quality in older adults – PubMed – https://pubmed.ncbi.nlm.nih.gov/38309227/
- 5-HTP adjunctive trial in obsessive-compulsive disorder – PubMed – https://pubmed.ncbi.nlm.nih.gov/32541380/
- 5-HTP and migraine prophylaxis – PubMed – https://pubmed.ncbi.nlm.nih.gov/3536521/
- 5-HTP and energy intake / weight in overweight diabetic patients – PubMed – https://pubmed.ncbi.nlm.nih.gov/9705024/
- 5-HTP pharmacology study with carbidopa – PubMed – https://pubmed.ncbi.nlm.nih.gov/18308795/
- FDA compounding-policy context for oral oxitriptan – FDA – https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compliance-policy-certain-compounding-oral-oxitriptan-5-htp-drug-products-patients
- EFSA opinion on 5-HTP and satiety / energy intake – EFSA – https://www.efsa.europa.eu/en/efsajournal/pub/2198
